Carigent Therapeutics Awarded NSF Phase I SBIR Grant to Advance Development of Paclitaxel-Loaded Targeted Nanoparticles to Treat Ovarian Cancer
1/22/2008 10:23:59 AM
More...
|
Carigent Therapeutics Awarded NCI Phase I SBIR Grant for Preclinical Development of Targeted, Long-Circulating Nanoparticle Therapeutic to Treat Non-Hodgkin’s Lymphoma
1/16/2008 10:25:47 AM
More...
|
Carigent Therapeutics Completes Series A Financing; Advancing Nanotechnology for Controlled Delivery of Targeted Drugs and Diagnostics -Engineered Nanoparticulate Delivery Systems to Improve Drug Targeting, Efficacy, and Safety
12/11/2007 6:27:00 AM
More...
|